Glimfirst-MP 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The sustained-release formulation ensures a gradual release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Glimfirst-MP 2 is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with any of its components. It should be used with caution in patients with hepatic or renal impairment, heart failure, or a history of bladder cancer due to the risk profile of Pioglitazone. Regular monitoring of blood glucose levels, liver function tests, and renal parameters is recommended during therapy. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.